From 160 to 130: How the Hypertension Threshold Moved
In 1970, a blood pressure of 160/95 was the threshold for concern. The rule of thumb used by many physicians was "100 plus your age" for an acceptable systolic reading. A 60-year-old with a pressure of 160/95 was considered normal. Over the next five decades, that number moved — not because human physiology changed, but because committees redefined it. Each time they did, the number of Americans with "hypertension" expanded by tens of millions. Each expansion was accompanied by an approved drug class ready to treat the newly minted patients.
The Timeline
What actually raises blood pressure — and what to ask
Blood pressure is a downstream measurement — it reflects what is happening upstream in the cardiovascular and neuroendocrine system. Documented, modifiable drivers that are almost never discussed at the time of prescription: magnesium deficiency (magnesium is the body's natural calcium channel blocker), non-native electromagnetic field (EMF) exposure activating voltage-gated calcium channels (VGCCs) in vascular smooth muscle, isolated vitamin D supplementation driving excess calcium into arterial walls, chronic sleep deprivation elevating sympathetic tone, the weight gain caused by thyroid dysfunction and antidepressant use that then drives blood pressure up, and habitual caffeine intake — which elevates blood pressure acutely and, with chronic high-dose use, sustains elevated sympathetic tone.
Questions worth asking: "Has my magnesium been tested — not serum, but RBC magnesium, which reflects actual tissue levels? Is my blood pressure consistently elevated across multiple settings, or does it reflect white coat response? What is the evidence for treating a reading of 132/82 specifically — what does it reduce my risk of, and by how much?"
The Cholesterol Threshold — From 240 to "It Depends on Your Risk Score"
Cholesterol treatment guidelines have been rewritten multiple times over four decades. Each revision lowered the threshold, expanded who qualified for treatment, and directly correlated with the approval of new drugs or the expansion of existing ones. The most recent change abandoned specific cholesterol numbers altogether — replacing them with a risk calculator so broad that approximately one in three American adults now qualifies for statin therapy. Cholesterol is a substrate the body uses to make sex hormones, bile acids, vitamin D, and every cell membrane in the human body. The narrative that it is primarily a cardiovascular villain was constructed in close collaboration with the industry that profits from lowering it.
Where the Numbers Started — and Where They Are Now
| Marker | Original "Normal" (1980s) | Current Threshold | Direction of Change |
|---|---|---|---|
| Total Cholesterol | Below 240 mg/dL = acceptable; only ≥240 with other risk factors warranted treatment | Below 200 mg/dL "desirable"; 200–239 "borderline high" | Lowered — more people in "high" category |
| LDL Cholesterol | LDL not widely used until 1993; first high-risk target ~<160 mg/dL (1987) | No target — statin decision based on 10-year risk calculator (2013). High-risk: LDL <70. Some guidelines now push <55 for "very high risk." | Progressively lowered — 160 → 130 → 100 → 70 → "no target needed" |
| HDL Cholesterol | Low HDL defined as <35 mg/dL; not a strong treatment target | Low HDL: <40 (men), <50 (women). But no drug has ever successfully raised HDL in a way that reduces cardiac events — multiple drug classes failed their clinical trials. | Threshold raised — more people classified as "low" |
| Triglycerides | Normal <200 mg/dL; treatment typically considered only above 400 mg/dL | Normal <150 mg/dL; "borderline high" 150–199. Fibrate drugs and now icosapentaenoic acid (Vascepa) marketed for elevated triglycerides — with disputed mortality benefit. | Lowered — range of "concern" significantly expanded |
The Timeline
What cholesterol actually is — and what statins take from the body
Cholesterol is not a toxin. It is a structural molecule required to build every cell membrane in the human body. It is the precursor to all sex hormones (estrogen, progesterone, testosterone, DHEA/dehydroepiandrosterone), cortisol, aldosterone, bile acids required for fat digestion, and the skin's production of vitamin D precursors. The brain is 25% cholesterol by weight. Driving LDL to extremely low levels has physiological consequences that include impaired hormone synthesis, reduced bile acid production, and in post-menopausal women, accelerated hormonal depletion — the very women most frequently prescribed statins.
Statins deplete Coenzyme Q10 (CoQ10) — the mitochondrial energy compound required for cardiac muscle contraction. The heart is the most CoQ10-dependent muscle in the body. A statin prescribed to protect the heart depletes the compound the heart most requires to generate energy. This depletion is documented, predictable, and almost never disclosed at the time of prescription.
The Oreo cookie study (2023): A Bowdoin College undergraduate research project found that eating Oreo cookies lowered LDL cholesterol as effectively as statin therapy in the student researcher's self-experiment — because dietary saturated fat triggers the liver to downregulate LDL receptor expression, while removing it prompts the liver to upregulate receptors and pull more LDL from circulation. The point is not that Oreos are healthy. The point is that LDL can be moved by many inputs — dietary, pharmaceutical, and otherwise — and that moving the number does not automatically equal reduced cardiovascular risk, which is the assumption underlying the entire statin market.
When cholesterol is pushed too low: brain fog, weakness, and arrhythmia
The current aggressive push — combining statins with PCSK9 inhibitors to drive total cholesterol to 100–150 mg/dL — is being marketed as a cardiovascular ideal. Clinically, this range produces a recognizable symptom cluster in a significant number of patients: cognitive impairment and brain fog, generalized muscle weakness and fatigue, and cardiac arrhythmia. When cholesterol is allowed to rise back toward physiological levels, these symptoms frequently resolve.
This is not surprising when you understand what cholesterol does:
Brain
The brain is 25% cholesterol by weight and synthesizes its own supply independently of serum cholesterol — but statins that cross the blood-brain barrier (lipophilic statins: simvastatin, atorvastatin, lovastatin) do suppress brain cholesterol synthesis. Cholesterol is required for myelin sheath integrity, synaptic vesicle formation, and neurosteroid production. Very low cholesterol is associated with increased risk of depression, cognitive decline, and — in population studies — dementia. Brain fog and memory impairment are among the most commonly reported statin side effects, often normalized or dismissed.
Muscle & Energy
Statins inhibit the mevalonate pathway — the same pathway that produces CoQ10. Every muscle cell depends on CoQ10 for mitochondrial energy production. Skeletal muscle weakness, myalgia, and in severe cases rhabdomyolysis (muscle breakdown) are documented statin effects. When total cholesterol is driven to 100–150 mg/dL via combined drug therapy, the physiological substrate for cell membrane repair, hormone synthesis, and energy production is severely depleted. Patients report weakness that clinicians attribute to age, deconditioning, or anxiety.
Heart Rhythm
Cardiac cell membranes require cholesterol for structural integrity and for the function of ion channels — particularly sodium and potassium channels — that govern the electrical impulses driving heart rhythm. Extremely low cholesterol impairs membrane fluidity and ion channel function. Statin-associated arrhythmia is documented in the literature and in FDA adverse event reports. The paradox: a drug prescribed to protect the heart can, via CoQ10 depletion and membrane disruption, destabilize the electrical system that keeps it beating regularly.
What to ask: If you are on a statin or PCSK9 inhibitor and experiencing brain fog, memory changes, muscle weakness, or new-onset arrhythmia — ask for a total cholesterol number, not just LDL. If your total cholesterol is below 160 mg/dL, consider whether the drug dose is appropriate and what physiological functions may be compromised. These symptoms are not always drug side effects — but they are not always age either.
Sunlight and cholesterol: UVB exposure in the skin converts cholesterol (specifically 7-dehydrocholesterol in the skin) into previtamin D3 — and separately, sunlight exposure is associated with higher HDL and lower LDL in population studies. Patients with minimal sun exposure reliably show elevated LDL in the absence of dietary changes. The body appears to use cutaneous cholesterol as a substrate for photoconversion; when sunlight is absent, that substrate accumulates. Before prescribing a statin for elevated LDL, asking about sun exposure is a clinically relevant question that is almost never posed.
Two Reference Ranges. Two Enormous Drug Markets.
Thyroid-stimulating hormone (TSH) and fasting blood glucose are two of the most commonly ordered lab values in medicine. Both have reference ranges that were established through committee consensus. Both have been the subject of ongoing redefinition debates — with industry-funded research on one side and independent practitioners on the other. In both cases, the direction of the debate expands the treatment population.
A note on senior TSH ranges — and why they make no clinical sense
Many laboratories and guidelines use age-adjusted TSH reference ranges that allow a higher upper limit in older adults — some labs list "normal" TSH as up to 6.0 or 7.0 mIU/L for patients over 70. The stated rationale is that TSH naturally rises slightly with age. The practical effect is that older adults — who are already the most vulnerable to hypothyroid symptoms (fatigue, cold intolerance, weight gain, cognitive slowing, constipation, depression, hair loss, dry skin, slow heart rate) — are given a wider range before any treatment is considered. Symptoms that would prompt investigation in a 35-year-old are attributed to normal aging in a 72-year-old with a TSH of 5.8 that the lab reports as "within range." The wider the permitted swing, the longer the suffering continues untreated — and the more easily it is dismissed as age rather than physiology.
Thyroid — TSH Reference Range
Typical age-adjusted upper limits in use:
Ages 20–39: up to 2.5–4.0 mIU/L
Ages 40–59: up to 4.0–4.5 mIU/L
Ages 60–69: up to 5.0–6.0 mIU/L
Ages 70+: up to 6.0–7.0 mIU/L (some guidelines: treat only above 10)
The TRUST trial (2017) is frequently cited to justify withholding treatment in older adults with subclinical hypothyroidism — it found no benefit to treating TSH 4.6–19.99 in patients over 65. But the trial used levothyroxine (T4 only), did not test T3 or combination therapy, and excluded patients with overt symptoms. The conclusion "treatment doesn't help" was then applied broadly to withhold evaluation.
The result: a 74-year-old with a TSH of 6.2, complaining of fatigue, constipation, weight gain, brain fog, and depression, receives a lab report that says "within normal range for age." Every symptom is attributed to getting older. The thyroid is not treated. The symptoms are treated with other drugs.
The suppressed TSH trap: over-medicated on paper, still hypothyroid in the body
A TSH of 0.5 mIU/L tells you one thing: the pituitary believes there is enough thyroid hormone circulating. It does not tell you whether the active thyroid hormone — T3 — is actually reaching the cells and doing its job. This distinction is the most commonly missed piece of thyroid management in older adults, and the failure to address it is clinical inertia with real consequences.
The T4 → T3 conversion problem
Levothyroxine (Synthroid, generic) provides T4 — the storage form of thyroid hormone. T4 must be converted to T3, the active form, by deiodinase enzymes (primarily in the liver, gut, and kidney). This conversion is impaired by: chronic inflammation, elevated cortisol, selenium deficiency, gut dysfunction, certain medications (amiodarone, beta-blockers, corticosteroids), and aging itself. A senior on levothyroxine for years may have a TSH of 0.5 — looking "suppressed" or well-dosed on paper — while their Free T3 is low and every hypothyroid symptom persists. The TSH is suppressed by the T4 load; the cells are still starved of active hormone.
Why the dose doesn't get adjusted
The standard of care is to dose levothyroxine to a TSH within range — typically 0.4–4.5, or the wider senior range. If TSH is 0.5, the doctor sees "low-normal" or "slightly suppressed" and either leaves the dose unchanged or reduces it. Free T3 and Free T4 are rarely ordered. Reverse T3 — the inactive form that blocks T3 receptors and accumulates under stress and poor conversion — is almost never checked. The patient reports ongoing fatigue, brain fog, weight gain, constipation, hair loss, and cold intolerance. These are documented hypothyroid symptoms. They are attributed to age. The medication is not changed. Sometimes it is reduced, making the problem worse.
What the labs should show — and what is almost never ordered
TSH
Routinely ordered. Tells you pituitary signaling, not cellular function. A suppressed TSH does not mean the patient is well.
Free T3 (rarely ordered)
The active hormone. Low Free T3 with suppressed TSH = conversion problem. Patient is receiving T4 but not using it. Symptoms will persist regardless of TSH.
Reverse T3 (almost never ordered)
The inactive form. When rT3 is elevated, it occupies T3 receptors and blocks active hormone. A patient can have adequate T3 levels but be functionally hypothyroid because rT3 is filling the receptor sites.
What to ask: "My TSH is low but I still have every hypothyroid symptom. Has my Free T3 been tested? Has my Reverse T3 been tested? Is T4-to-T3 conversion being evaluated — or are we only managing the TSH number?" A senior whose TSH is 0.5 and who still feels hypothyroid is not over-medicated. They may be under-converting. Those are two entirely different clinical situations requiring two entirely different responses — and they are almost never distinguished.
Blood Sugar — The Prediabetes Creation
The test that would catch it early — and is almost never ordered
Fasting glucose can remain entirely normal for 10–15 years while insulin resistance is developing and worsening. The reason: the pancreas compensates by producing more and more insulin to force glucose into cells. Fasting glucose stays in the normal range — because the body is working overtime to keep it there. Insulin is never tested. The problem is invisible until the pancreas can no longer compensate and glucose finally rises.
By the time fasting glucose reaches 100 mg/dL — the threshold now called "prediabetes" — insulin resistance has typically been present for a decade. By the time a patient is diagnosed with type 2 diabetes, approximately 50% of pancreatic beta-cell function has already been lost.
Fasting Glucose
Routinely ordered. Normal: <100 mg/dL. What it misses: a person with a fasting glucose of 88 and a fasting insulin of 22 µIU/mL has severe insulin resistance. The glucose looks perfect. The insulin is doing all the heavy lifting to keep it there — and is burning out the beta cells in the process.
Fasting Insulin (rarely ordered)
Optimal fasting insulin: 2–5 µIU/mL. Most labs list "normal" as up to 25 µIU/mL — a range so wide it hides early dysfunction. And like glucose, this upper limit has been revised downward over time: older lab standards accepted values up to 30–35 µIU/mL; newer references use 25; functional practitioners use 10 as the upper limit of acceptable. The direction of revision is appropriate here — yet even the improved threshold is rarely applied because the test itself is rarely ordered. A fasting insulin above 10 in a patient with normal fasting glucose indicates compensatory hyperinsulinemia: insulin resistance already in progress, glucose not yet raised. This is the window to intervene — and it is almost always missed.
HOMA-IR (calculated)
Homeostatic Model Assessment of Insulin Resistance — calculated from fasting glucose and fasting insulin: (glucose × insulin) ÷ 405. Optimal: below 1.0. Above 1.9 indicates early insulin resistance; above 2.9 indicates significant resistance. This calculation requires only two lab values that are both inexpensive to run — and is virtually never included in a standard metabolic panel.
What to ask: "Has my fasting insulin ever been tested — not just my fasting glucose? Can we calculate my HOMA-IR?" If the answer is that this test has never been run, you have been screened for the late-stage symptom (high glucose) while the early-stage driver (high insulin) was never evaluated. The standard of care tests the last domino to fall.
Three More Ranges That Moved
Blood pressure, cholesterol, thyroid, and blood sugar get the most attention — but they are not the only reference ranges that have shifted to expand the treatable population. Liver enzymes, kidney function, and bone density all have definitions of "normal" that reward investigation.
Liver Enzymes — ALT and the "Normal" That Isn't
Alanine aminotransferase (ALT) is the primary marker of liver cell injury. The upper limit of "normal" for ALT ranges from lab to lab — and has been set using population samples that include individuals with non-alcoholic fatty liver disease (NAFLD), medication-induced liver stress, and alcohol use. When the reference population is already metabolically compromised, the resulting "normal" range is artificially high.
The Range Problem
- → Most lab "normal": ALT ≤ 40–56 U/L (varies by lab)
- → Prati et al. (2002, Annals of Internal Medicine): After excluding individuals with metabolic risk factors, the true upper limit of normal for healthy adults is approximately 30 U/L for men, 19 U/L for women
- → A patient with ALT of 45 is told their liver enzymes are "normal" — but by a reference population that included people with NAFLD and medication burden
- → Significant liver pathology (early fibrosis, steatosis) can exist with ALT readings within the lab's "normal" range
Why This Matters
- → Statins are monitored with liver enzymes — but the reference range for "safe" may mask early statin hepatotoxicity
- → Multiple medications elevate liver enzymes within "normal" range — the damage accumulates below the threshold of concern
- → Acetaminophen (the #1 cause of acute liver failure in the US) can produce significant glutathione depletion with ALT still technically "normal"
- → A consistently elevated ALT of 38 in a woman — "normal" by most labs, but nearly double the true upper limit for healthy women — is a meaningful signal
Kidney Function — The CKD Staging Expansion
Chronic kidney disease (CKD) staging was introduced in 2002 by the National Kidney Foundation. The estimated glomerular filtration rate (eGFR) — a calculated estimate of kidney filtering capacity — became the primary measurement, and five stages of CKD were defined. The threshold for CKD Stage 3 (eGFR 30–59) and the 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guideline update created a diagnosis of chronic kidney disease in populations who had previously been told their kidneys were functioning adequately for their age.
The Age-Correction Problem
Kidney function declines naturally with age — eGFR decreases approximately 1 mL/min/1.73m² per year after age 40. An 80-year-old with an eGFR of 52 may have completely normal age-appropriate kidney function — but under CKD staging criteria, they have Stage 3 Chronic Kidney Disease. A 2011 paper in BMJ estimated that applying the 2012 KDIGO criteria to the elderly population would classify approximately 50% of adults over age 75 as having CKD — the majority of whom had no kidney disease by any functional definition. The diagnosis creates a patient for nephrology follow-up, dietary restrictions, and medication review that may not be clinically warranted.
BUN and Creatinine — What the Numbers Mean and What Distorts Them
The eGFR is calculated from creatinine — not measured directly. Creatinine and BUN (blood urea nitrogen) are the two primary kidney markers on a standard metabolic panel, and both have significant interpretation problems that are rarely explained to patients.
| Marker | Standard Lab Range | Optimal / Functional | What Raises It (Non-Kidney Causes) | What Lowers It (Non-Kidney Causes) |
|---|---|---|---|---|
| Creatinine | Men: 0.7–1.3 mg/dL Women: 0.5–1.1 mg/dL |
Men: 0.8–1.1 Women: 0.6–0.9 (with normal muscle mass) |
High muscle mass (athletes), high red-meat intake, intense exercise, dehydration, certain medications (trimethoprim, cimetidine) | Low muscle mass (frailty, cachexia, elderly), low protein diet, pregnancy — a frail 80-year-old with creatinine of 0.7 may have worse kidney function than a muscular 40-year-old with creatinine of 1.2 |
| BUN (Blood Urea Nitrogen) | 7–25 mg/dL (some labs: 8–20) | 10–16 mg/dL | High protein diet, dehydration, GI bleeding (blood is protein), catabolic states (fever, trauma, corticosteroids), congestive heart failure | Malnutrition, very low protein intake, liver disease (urea requires liver to produce), overhydration — a low BUN in an elderly patient may signal malnutrition, not good kidney health |
| BUN:Creatinine Ratio | 10:1 to 20:1 | 12:1 to 16:1 | Ratio >20: dehydration, GI bleed, high protein intake, heart failure — kidney structure may be intact but pre-renal factors are at work | Ratio <10: liver disease, low protein intake, muscle breakdown — both markers suppressed; ratio normalizes but function may be poor |
The muscle mass problem — and why frail elderly are systematically misread
Creatinine is produced by muscle tissue. The eGFR formula assumes a normal level of muscle mass for age and sex — but does not measure it. A frail 78-year-old woman who has lost significant muscle mass from years of inactivity, malnutrition, or chronic illness will produce very little creatinine. Her creatinine reads 0.68 — "normal." The formula calculates an eGFR of 74 — "normal kidney function." In reality her kidneys may be filtering poorly, but the low creatinine input makes the calculated output look fine. This is not a rare edge case: sarcopenia (age-related muscle loss) is nearly universal in the elderly and makes standard creatinine-based eGFR systematically unreliable in this population.
Cystatin C is an alternative kidney marker not affected by muscle mass — produced by all nucleated cells at a constant rate, independent of age, sex, or muscle. It is a more accurate indicator of kidney function in elderly, frail, or very lean patients. It is rarely ordered. When it is ordered and compared to the creatinine-based eGFR, the gap frequently reveals that kidney function is worse than the standard panel suggested — or in some cases, better, catching patients who were over-staged due to high muscle mass.
What a CKD diagnosis enables — and what it restricts
A CKD diagnosis — even Stage 3 in an 80-year-old with entirely age-appropriate eGFR — triggers a cascade: nephrology referral, protein restriction (often unnecessary and harmful in elderly patients already eating too little), phosphorus restriction, potassium restriction, discontinuation of NSAIDs, and increasingly, prescription of SGLT-2 inhibitors (empagliflozin, dapagliflozin) now approved specifically for CKD — regardless of whether diabetes is present. The SGLT-2 inhibitor approval for CKD in 2021 created a new indication for a drug class whose mechanism (forcing glucose excretion through the kidneys) raises questions about long-term renal tubular stress.
Protein restriction in elderly CKD patients deserves specific attention: the fear of protein "stressing the kidneys" has led to dietary recommendations that accelerate sarcopenia in populations already losing muscle. For patients in earlier CKD stages, the evidence for protein restriction as a disease-modifying intervention is weak — and the harm from inadequate protein in aging muscle is well documented.
Bone Density — Osteoporosis and the T-Score
In 1994, the World Health Organization introduced the T-score definition of osteoporosis: a bone density more than 2.5 standard deviations below the mean of a young adult reference population. The reference population chosen was young white women at peak bone density — meaning the standard against which all older women (and men) are measured is peak youth. Under this definition, the natural and expected bone density reduction that occurs with aging becomes a diagnosable disease.
The DEXA scan measures density — not bone quality, architecture, or living bone
Dual-energy X-ray absorptiometry (DEXA) measures how much mineral is present in a cross-section of bone. It does not measure whether that bone is alive, structurally sound, properly remodeled, or capable of absorbing impact without fracturing. This distinction is the central problem with bisphosphonate therapy — and it is almost never explained.
The radiation problem: DEXA delivers ionizing radiation — approximately 1–10 µSv per scan (lower than a chest X-ray, but not zero). Ionizing radiation damages DNA in the cells it passes through — including osteoblasts, the bone-forming cells the scan is supposed to monitor. Osteoblasts are post-mitotic in mature bone but their precursor cells (osteoprogenitor cells in the bone marrow) are actively dividing and radiosensitive. Repeated annual DEXA scanning, particularly when begun in middle age, delivers cumulative ionizing radiation directly to the tissue whose health is being assessed. The scan that monitors bone health contributes — incrementally — to the DNA damage in bone-forming cells. This is not a reason never to have a DEXA scan. It is a reason not to have one annually without clinical justification, and to understand that the test is not neutral.
How bisphosphonates distort the DEXA reading: Healthy bone is continuously remodeled — osteoclasts dissolve old, microdamaged bone; osteoblasts build new bone in its place. This cycle takes approximately 3–4 months and is how bone maintains its strength. Bisphosphonates inhibit osteoclast activity — shutting down the resorption side of the cycle. Old, fatigued bone accumulates rather than being replaced. The DEXA scan registers more mineral mass (the dead bone is still there) and reports improved density. The T-score improves. The patient is told the drug is working. But the bone has not been remodeled — it is denser and more brittle, carrying microfractures that were never cleared. The result, in long-term users (5–10 years), is atypical subtrochanteric femoral fractures — complete transverse breaks of the thigh bone under minimal stress — and medication-related osteonecrosis of the jaw (MRONJ).
Joint replacements and the downstream picture: Compromised bone quality — from long-term bisphosphonate use, nutritional depletion, and the drivers below — contributes to the periprosthetic fracture rate after hip and knee replacement. Surgeons implanting hardware into bone that looks dense on imaging but is structurally dead encounter fixation failures. The bone that was supposed to be treated is no longer capable of holding the repair.
Medications that cause osteopenia and bone loss — almost never flagged at the time of a DEXA result:
Corticosteroids (prednisone, dexamethasone, inhaled ICS)
Directly suppress osteoblast activity and stimulate osteoclasts. Glucocorticoid-induced osteoporosis (GIOP) is the most common drug-induced bone disease — significant bone loss begins within the first 3–6 months of use. Even inhaled corticosteroids (fluticasone, budesonide) at higher doses have documented effects on bone density in long-term users. Patients on long-term steroids for asthma, IBD, rheumatoid arthritis, or lupus accumulate years of osteoblast suppression that registers on DEXA as "osteopenia" with no mention of the causative drug.
Hormonal Birth Control — Progestins and Synthetic Estrogen
Depot medroxyprogesterone acetate (Depo-Provera) carries an FDA Black Box Warning for bone density loss — it suppresses endogenous estrogen production, and estrogen is required for osteoblast activity and bone maintenance. Studies show significant bone density reductions within 2 years of Depo use. Combined oral contraceptives can also suppress bone accrual in adolescents and young women during the critical window of peak bone mass development (ages 16–25). A woman who spent her bone-building years on the pill, then used Depo in her 30s, arrives at menopause with a bone density baseline already compromised — and receives a bisphosphonate prescription that treats the T-score rather than the history that produced it.
Proton Pump Inhibitors (PPIs)
Gastric acid is required for calcium absorption — particularly calcium carbonate, the most common form in food and supplements. PPIs suppress acid so effectively that calcium absorption is significantly impaired. Long-term PPI use is associated with increased fracture risk at the hip, wrist, and spine — FDA safety communication issued in 2010. The patient is prescribed a PPI for acid reflux; years later their DEXA shows osteopenia; they are prescribed a bisphosphonate. The PPI continues. The acid suppression continues. The calcium absorption problem continues. The bisphosphonate addresses the downstream measurement without touching the upstream cause.
SSRIs, Anticonvulsants, Aromatase Inhibitors, Heparin
SSRIs: serotonin receptors on osteoblasts and osteoclasts regulate bone remodeling; SSRI use is associated with increased fracture risk independent of fall risk. Anticonvulsants (phenytoin, carbamazepine, valproate): induce liver enzymes that metabolize vitamin D, accelerating its breakdown and reducing calcium absorption — well-documented cause of drug-induced osteomalacia. Aromatase inhibitors (anastrozole, letrozole) — prescribed for hormone-positive breast cancer — suppress estrogen to near-zero; bone density loss is a major documented effect. Heparin (long-term): directly inhibits osteoblast activity. None of these appear in the conversation when a DEXA result comes back as osteopenic.
What is actually driving the bone loss — and what the prescription conversation never reaches
Bone density is downstream of bone metabolism — and bone metabolism is affected by a set of modifiable inputs that are documented in the literature but almost never discussed at the time of a DEXA scan result and bisphosphonate prescription.
Non-Native EMF — Voltage-Gated Calcium Channels
Bone is a piezoelectric tissue — it generates electrical signals in response to mechanical stress, and those signals drive osteoblast (bone-building) activity. This is why weight-bearing exercise builds bone. Non-native EMF — from cell phones, cars (which act as Faraday cages concentrating ELF fields around the body), Wi-Fi, and medical imaging devices — activates voltage-gated calcium channels (VGCCs) in cell membranes throughout the body, including in bone cells. Dysregulated calcium signaling in osteoblasts and osteoclasts disrupts the remodeling cycle. The unprecedented saturation of EMF in modern environments — in every car, every room, every pocket — represents a calcium signaling disruption operating continuously at a scale no prior generation experienced.
Caffeine — Calcium Excretion and Cortisol
Caffeine increases urinary calcium excretion — each 6 mg of caffeine consumed is associated with approximately 1 mg of calcium lost in urine. At habitual high intakes (300–500 mg/day, common in coffee drinkers), cumulative calcium loss is meaningful over years. Caffeine also stimulates cortisol secretion; elevated cortisol directly inhibits osteoblast activity and increases osteoclast activity — the opposite of what you want for bone density. Population studies consistently show inverse associations between high caffeine intake and bone density, particularly in women with low dietary calcium. This is not mentioned in the DEXA result conversation.
Medical Procedures — Radiation and Contrast
Ionizing radiation damages bone marrow and bone-forming cells. Patients with histories of radiation therapy — even to adjacent fields — often have locally impaired bone metabolism in the treated area. The cumulative CT scan burden in chronic patients represents significant ionizing radiation exposure over years. Iodinated contrast agents used in CT and angiography cause transient but repeated oxidative stress and, in patients with marginal kidney function, nephrotoxicity that secondarily affects calcium and phosphorus metabolism. DEXA itself uses low-dose X-ray — adding incrementally to cumulative radiation burden when ordered annually.
Dental Cavitations — The Jawbone Connection
Cavitations are areas of ischemic osteonecrosis in the jawbone — regions where blood supply has been compromised, bone has died, and the empty space (cavitation) is not visible on standard dental X-ray. They develop at sites of tooth extractions (especially wisdom teeth) where healing was incomplete, and are significantly more common in patients on bisphosphonates (MRONJ — medication-related osteonecrosis of the jaw), but also occur independent of drug use in patients with poor bone metabolism, high heavy metal burden, and compromised microcirculation. Biological dentists identify cavitations as a source of chronic systemic inflammation and a window into the quality of bone metabolism throughout the body — not just the jaw. A patient whose jawbone is forming cavitations is not building and maintaining bone correctly anywhere.
What to ask before accepting a bisphosphonate prescription: "Has my calcium, magnesium, phosphorus, vitamin K2 status, protein intake, weight-bearing activity level, and cortisol been evaluated? Has anyone asked about my EMF environment, caffeine intake, or medication history? What is driving the bone loss — and has that been addressed? If I take this drug for five years and it keeps dead bone in my skeleton, what happens when I stop — and what is my risk of atypical fracture and jaw osteonecrosis?"
How "Normal" Gets Redefined — And Who Decides
Across blood pressure, cholesterol, thyroid, blood sugar, liver enzymes, kidney function, and bone density, the pattern is consistent: the definition of disease expands, the population eligible for treatment grows, and the growth correlates with the availability of drugs to treat the newly expanded category. This is not a conspiracy. It is an incentive structure — and understanding it is the first step toward reading your own lab results with appropriate context.
The Committee-Industry Pipeline
Medical reference ranges and treatment guidelines are set by expert committees — panels of specialists convened by medical associations, government agencies, or international bodies. These committees are staffed by the leading researchers in their fields. Many of those researchers have financial relationships with pharmaceutical companies — consulting fees, speaker honoraria, research funding, advisory board positions.
A 2011 analysis published in the Archives of Internal Medicine reviewed 14 clinical practice guidelines and found that 56% of the authors had financial ties to pharmaceutical companies related to the drugs in those guidelines. For the most commercially significant guidelines (cholesterol, diabetes, hypertension), the proportion was higher.
This does not mean every guideline change is corrupt. It means that the process by which "normal" is defined is not a purely scientific one. It is a human process, conducted by people with professional and financial interests, operating in an industry where the commercial consequences of guideline changes are measured in billions of dollars.
The Recurring Pattern — By the Numbers
| Condition | Previous Threshold | New Threshold | New Patients Created | Drug Class Available |
|---|---|---|---|---|
| Hypertension | 160/100 (1977) | 130/80 (2017) | +31 million (2017 alone) | ACE inhibitors, ARBs, calcium channel blockers, beta-blockers |
| High Cholesterol | Total ≥ 240 (1984) | Risk-score based (2013) | ~1 in 3 adults eligible | Statins, PCSK9 inhibitors, ezetimibe |
| Diabetes | Fasting glucose ≥ 140 (pre-1997) | ≥ 126 + prediabetes ≥ 100 (2003) | +86 million "prediabetes" | Metformin, GLP-1 agonists, SGLT-2 inhibitors |
| Hypothyroid | TSH ≥ 5.0 (original labs) | Debated — most labs 4.0–4.5 still; functional 2.5 | Millions in 2.5–4.5 range untreated but symptomatic | Levothyroxine (#1 US prescription) |
| Osteoporosis | No T-score definition (pre-1994) | T-score ≤ −2.5 vs. peak young adult female bone | Majority of post-menopausal women | Bisphosphonates (approved 1995) |
| Chronic Kidney Disease | Clinical judgment, advanced dysfunction | eGFR staging from 2002; 2012 KDIGO expansion | ~50% of adults >75 under KDIGO criteria | ACE inhibitors, ARBs, SGLT-2 inhibitors |
Questions to Ask When Given a Lab Result
Drugs That Cause the Disease They Treat — Or Create the Next One
The most under-examined pattern in pharmaceutical medicine is the feedback loop: a drug prescribed for one condition creates the biological conditions for another — which is then treated with a second drug. The new condition may appear years later, in a different organ system, and the connection to the original prescription is rarely made in a standard clinical encounter. Below are documented examples — not speculation, but labeled side effects, pharmacological mechanisms, and outcomes recorded in the medical literature and FDA adverse event databases.
Statins → Diabetes
Statins are associated with a 10–12% increased risk of new-onset type 2 diabetes — a finding confirmed across multiple large trials and acknowledged in FDA labeling since 2012. The mechanism: statins reduce insulin secretion from pancreatic beta cells (which require the mevalonate pathway for normal function) and increase insulin resistance in muscle cells. A patient prescribed a statin for high cholesterol develops diabetes within 3–5 years. The diabetes is then treated with metformin, a GLP-1 agonist, or an SGLT-2 inhibitor. The statin is rarely reconsidered as a contributing cause.
→ Metformin / GLP-1
Antihypertensives → Sexual Dysfunction → Antidepressants
Beta-blockers and thiazide diuretics — two of the most commonly prescribed antihypertensive classes — have sexual dysfunction as a documented, common side effect. Erectile dysfunction from antihypertensives is well established; reduced libido and anorgasmia in women is documented but less studied. The sexual dysfunction leads to depression, relationship strain, and quality of life decline. An antidepressant is often added — which itself commonly causes sexual dysfunction, weight gain, and emotional blunting. The original antihypertensive is rarely identified as the starting point.
→ Depression → SSRI
SSRIs → Weight Gain → Metabolic Disease → Hypertension
Antidepressants — particularly SSRIs and especially paroxetine (Paxil) and mirtazapine — are associated with significant weight gain in long-term use. The weight gain drives insulin resistance, elevated fasting glucose, dyslipidemia, and elevated blood pressure. A patient who was normotensive and non-diabetic before beginning an antidepressant is, three to five years later, on a blood pressure medication and approaching a prediabetes diagnosis. Each new condition is treated as independent. The antidepressant sits at the origin of the cascade, rarely examined.
→ HTN + prediabetes → new prescriptions
Proton Pump Inhibitors → Magnesium Deficiency → Hypertension + Arrhythmia
PPIs (omeprazole, esomeprazole, pantoprazole) suppress gastric acid required for magnesium absorption. Long-term PPI use causes hypomagnesemia — FDA warning issued in 2011. Magnesium is the body's natural calcium channel blocker and is required for vascular smooth muscle relaxation and cardiac electrical stability. Magnesium deficiency drives elevated blood pressure and cardiac arrhythmia — particularly atrial fibrillation. A patient on a PPI for acid reflux develops elevated blood pressure (treated with an antihypertensive) and atrial fibrillation (treated with an antiarrhythmic or anticoagulant). The PPI, still running in the background, is the origin. It is almost never stopped.
→ HTN + A-fib → more drugs
Bisphosphonates → Atypical Fractures → Joint Replacement → Surgical Complications
As described in the bone density section: bisphosphonates suppress osteoclast activity, accumulate dead bone in the skeleton, improve DEXA scores, and in long-term users produce atypical subtrochanteric femoral fractures — complete transverse breaks under minimal stress. These fractures frequently require surgical fixation or hip replacement. The hip replacement is performed in bone that has been pharmacologically altered for years — periprosthetic fracture rates are higher, osseointegration of implants is impaired, and the surgical complications are attributed to age and bone fragility rather than to the drug that altered the bone biology. The drug prescribed to prevent fractures contributed to the fracture. The surgery required to fix it carries its own complication profile. The trajectory from DEXA scan to operating table is a straight line that is almost never acknowledged as such.
→ Joint replacement → surgical risk
Corticosteroids → Osteoporosis + Hyperglycemia + Adrenal Suppression
Corticosteroids (prednisone, dexamethasone, methylprednisolone) — prescribed for autoimmune conditions, inflammatory disease, asthma, and many other conditions — directly suppress osteoblast activity, driving bone loss significant enough to produce steroid-induced osteoporosis. They also elevate blood glucose (steroid hyperglycemia), often requiring insulin or oral diabetes medication during use. Long-term or repeated use suppresses the HPA axis, leading to adrenal insufficiency — a condition that then requires careful steroid taper, supplementation, and long-term monitoring. A patient who received corticosteroids for inflammatory bowel disease, asthma, or a rheumatologic condition may leave with osteoporosis, steroid-induced diabetes, and adrenal suppression — each of which generates its own prescription and monitoring cascade. The steroid is the common origin of all three.
+ Diabetes + Adrenal suppression
The cascade is the business model
Each of the above is a documented pharmacological mechanism — not speculation. The cascade from one drug to the next generates additional prescriptions, additional monitoring visits, additional specialist referrals, and additional procedures. A patient who begins with one prescription at age 50 for a borderline lab value may be on six medications by age 65 — each one treating something the previous one contributed to. This is not always intentional. It is the predictable outcome of a system that treats each new diagnosis as independent, rarely looks backward at medication history as a contributing cause, and has no financial incentive to identify drug-induced disease and stop the originating prescription.
This is not anti-medicine. It is informed medicine.
The information on this page is not an argument against treating elevated blood pressure, high cholesterol, diabetes, or thyroid disease. These are real conditions with real consequences. It is an argument for understanding the context of the number you are given — how it was defined, when the definition changed, and whether the distance between your result and the threshold represents meaningful clinical risk or a recently moved line. Informed consent means understanding what "borderline" actually means — and making decisions with that full picture rather than responding to a number on a printout without its history.